Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Foos

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of Medical Economics|October 18, 2014
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluationMarc Evans, Phil McEwan, Volker Foos
Current Medical Research and Opinion|November 19, 2009
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and SpainSandra L Tunis, William D Willis, Volker Foos
Diabetes, Obesity & Metabolism|March 2, 2023
Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidencePhil McEwan, Volker Foos, Becky Martin, et al.
In Silico Biology|June 23, 2006
CorrXpression--identification of significant groups of genes and experiments by means of correspondence analysis and ratio analysisRalf Wessel, Volker Foos, Allan Aspelmeier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 12, 2019
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular DiseaseMafalda Ramos, Volker Foos, Anastasia Ustyugova, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
Validation of the IMS CORE Diabetes ModelPhil McEwan, Volker Foos, James L Palmer, et al.
Pharmacoeconomics|July 14, 2020
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management InterventionsSandra Lopes, Pierre Johansen, Mark Lamotte, et al.
Current Medical Research and Opinion|December 22, 2005
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK settingWilliam J Valentine, Andrew J Palmer, Morten Lammert, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 29, 2008
Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactiveWilliam J Valentine, Daniel Tucker, Andrew J Palmer, et al.
Diabetes, Obesity & Metabolism|January 20, 2025
Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff modelPhil McEwan, Volker Foos, Geraint Roberts, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Medical Economics|October 18, 2014
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluationMarc Evans, Phil McEwan, Volker Foos
Current Medical Research and Opinion|November 19, 2009
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and SpainSandra L Tunis, William D Willis, Volker Foos
Diabetes, Obesity & Metabolism|March 2, 2023
Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidencePhil McEwan, Volker Foos, Becky Martin, et al.
In Silico Biology|June 23, 2006
CorrXpression--identification of significant groups of genes and experiments by means of correspondence analysis and ratio analysisRalf Wessel, Volker Foos, Allan Aspelmeier, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 12, 2019
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular DiseaseMafalda Ramos, Volker Foos, Anastasia Ustyugova, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
Validation of the IMS CORE Diabetes ModelPhil McEwan, Volker Foos, James L Palmer, et al.
Pharmacoeconomics|July 14, 2020
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management InterventionsSandra Lopes, Pierre Johansen, Mark Lamotte, et al.
Current Medical Research and Opinion|December 22, 2005
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK settingWilliam J Valentine, Andrew J Palmer, Morten Lammert, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 29, 2008
Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactiveWilliam J Valentine, Daniel Tucker, Andrew J Palmer, et al.
Diabetes, Obesity & Metabolism|January 20, 2025
Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff modelPhil McEwan, Volker Foos, Geraint Roberts, et al.
Pageof 3